Osteoblastoma response to radiotherapy and chemotherapy

Berberoĝlu, Semha; Oğuz, Aynur; Arıbal, Erkin; Ataoğlu, Ömür

doi:10.1002/(sici)1096-911x(199704)28:4<304::aid-mpo11>3.0.co;2-c

Cited by 40 publications

(26 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…11 Radiotherapy and chemotherapy, either together or individually, have been used for patients with unresectable lesions or in cases of recurrent disease. 5 Recurrence-free survival of up to 25 years after adjuvant radiotherapy has been reported in the literature. 16,87 The optimal dose for radiation has been reported to be a fractionated dose of 50 Gy, giving 2 Gy for 5 days per week, over the course of 5 weeks.…”

Section: Adjuvant Therapymentioning

confidence: 99%

“…Polytherapy has been shown to yield progression-free survival up to 33 months. 5,15,87 Bufotalin has been investigated for its potential induction of apoptosis in osteoblastoma cells. Zhu and colleagues have demonstrated in an animal model that endoplasmic reticulum stress activation contributes to bufotalininduced osteoblastoma cell death.…”

Section: Adjuvant Therapymentioning

confidence: 99%

See 1 more Smart Citation

Osteoblastomas of the spine: a comprehensive review

Galgano¹,

Goulart²,

Iwenofu

et al. 2016

FOC

View full text Add to dashboard Cite

Osteoblastomas are primary bone tumors with an affinity for the spine. They typically involve the posterior elements, although extension through the pedicles into the vertebral body is not uncommon. Histologically, they are usually indistinguishable from osteoid osteomas. However, there are different variants of osteoblastomas, with the more aggressive type causing more pronounced bone destruction, soft-tissue infiltration, and epidural extension. A bone scan is the most sensitive radiographic examination used to evaluate osteoblastomas. These osseous neoplasms usually present in the 2nd decade of life with dull aching pain, which is difficult to localize. At times, they can present with a painful scoliosis, which usually resolves if the osteoblastoma is resected in a timely fashion. Neurological manifestations such as radiculopathy or myelopathy do occur as well, most commonly when there is mass effect on nerve roots or the spinal cord itself. The mainstay of treatment involves surgical intervention. Curettage has been a surgical option, although marginal excision or wide en bloc resection are preferred options. Adjuvant radiotherapy and chemotherapy are generally not undertaken, although some have advocated their use after less aggressive surgical maneuvers or with residual tumor. In this manuscript, the authors have aimed to systematically review the literature and to put forth an extensive, comprehensive overview of this rare osseous tumor.

show abstract

Section: Adjuvant Therapymentioning

confidence: 99%

Section: Adjuvant Therapymentioning

confidence: 99%

Osteoblastomas of the spine: a comprehensive review

Galgano¹,

Goulart²,

Iwenofu

et al. 2016

FOC

View full text Add to dashboard Cite

show abstract

“…2 Since then, it has not been significantly ameliorated. 3,4 The malignant osteosarcoma is among the most intrinsically resistant malignancies to almost all chemotherapeutic drugs. 5,6 As such, recent research effects have been focusing on searching for the novel and more efficient agents against this disease.…”

Section: Introductionmentioning

confidence: 99%

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma

Zhu¹,

Min

Fang³

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

Keywords: MEK/Erk and chemo-resistance, NVP-BEZ235, osteosarcoma, PI3K-Akt-mTOR signaling Abbreviations: mammalian target of rapamycin (mTOR); mTOR complex 1 (mTORC1); mTOR complex 2 (mTORC2); phosphoinositide-dependent protein kinase-1 (PDK1); phosphatidylinositol 3-kinase (PI3K); receptor tyrosine kinases (RTKs).Recent studies have identified that constitutively active phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling is an important feature of osteosarcoma, where it promotes cell proliferation, survival, and chemo-resistance. Here, we studied the therapeutic potential of NVP-BEZ235, a novel dual PI3K/mTOR dual inhibitor, on osteosarcoma cells in vivo and in vitro. NVP-BEZ235 was cytotoxic and cytostatic to a panel of osteosarcoma lines (MG-63, U2OS and SaOs-2), where it induce apoptosis and cell-cycle arrest. At the molecular level, NVP-BEZ235 inhibited PI3K-AKT-mTORC1 activation and downregulated cyclin D1/cyclin B1 expressions, while increasing MEK/Erk phosphorylation in osteosarcoma cells. MEK/Erk inhibitors PD98059 and MEK-162 increased NVP-BEZ235 activity on osteosarcoma cells. In vivo, oral NVP-BEZ235 inhibited U2OS xenograft in SCID mice, and its antitumor efficiency was further enhanced by MEK-162 co-administration. Taken together, our findings indicate that dual inhibition of PI3K and mTOR with NVP-BEZ235, either alone or in combination with MEK/Erk inhibitors, may be an efficient treatment for osteosarcoma.

show abstract

“…different modes of management involving osteoid osteoma and osteoblastoma have been assessed. they include radiotherapy, chemotherapy (15,16) and percutaneous radiofrequency ablation (3). the methods mentioned above may be useful particularly in patients with recurrent aggressive tumors or in patients with surgically unresectable tumors.…”

Section: Discussionmentioning

confidence: 99%

Aggressive osteoblastoma of the sphenoid bone

Kukwa¹,

Oziȩbło²,

Oecińska³

et al. 2010

Oncology Letters

View full text Add to dashboard Cite

Abstract. For osteoblastoma, with its predilection for the spinal column and appendicular skeleton, the skull is an unusual site, and paranasal sinus involvement is very rare. Herein, we report on a case in which the disease was located within the sphenoid bone. to the best of our knowledge, this is the 4th reported case of osteoblastoma with a sphenoid origin (1). We report an osteoblastoma of the sphenoid sinus in a 12-year-old girl who presented with exophthalmos. computed tomography (ct) demonstrated an expansile lesion of the sphenoid which caused the orbital contents to be compressed and deviated to the right. In the magnetic resonance imaging scan, the lesion was found to invade the cranial base in the frontal and temporal region, approximating to the cavernous sinus and internal carotid artery on the right. Bilateral fronto-orbital craniotomy was performed. Histologically, the lesion was composed of proliferating osteoblasts along with vascular stroma. the tumor was described as an aggressive osteoblastoma. In the follow-up ct four months later, a pathological mass was observed in the area of the nasal septum, and a signal void was present on all sequences in the densely sclerotic areas. A second resection was performed. the patient has been disease-free for 61 months. Herein, we present the diagnosis and management of this unusual lesion. the histopathology and the imaging characteristics are shown.

show abstract

Osteoblastoma response to radiotherapy and chemotherapy

Cited by 40 publications

References 20 publications

Osteoblastomas of the spine: a comprehensive review

Osteoblastomas of the spine: a comprehensive review

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma

Aggressive osteoblastoma of the sphenoid bone

Contact Info

Product

Resources

About